Researchers at UCLA have developed a method to turn cord blood stem cells into cancer-fighting T cells that can be used off the shelf. These engineered cells are designed to attack solid tumors using two separate detection systems, which may help overcome the challenge of tumor heterogeneity.
In mouse models, a single dose of these T cells was enough to control tumor growth and extend survival. The treatment also sidestepped a serious side effect that often complicates conventional T cell therapies, though the source does not specify which complication.
The findings suggest a potential path toward more accessible and safer cell-based immunotherapies for solid tumors, but further research is needed to confirm efficacy in humans.